Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10495189 | 0.86 | TSHR (0.50) | TSHRTRPA1LMNAKMT2AHSD17B10 | |
| SCHEMBL3972649 | 0.84 | LMNA (0.48) | TSHRTRPA1LMNAKMT2AHSD17B10 | |
| SCHEMBL4861479 | 0.82 | TSHR (0.50) | TSHRLMNAKMT2AHSD17B10TDP1 | |
| SCHEMBL10495218 | 0.82 | TSHR (0.50) | TSHRLMNAKMT2AHSD17B10TDP1 | |
| SCHEMBL5479626 | 0.78 | TRPA1 (0.52) | TRPA1SLC6A4HDAC3HDAC1HDAC2 | |
| SCHEMBL11130477 | 0.77 | TSHR (0.52) | TSHRLMNAKMT2AHSD17B10TDP1 | |
| SCHEMBL15719781 | 0.75 | TSHR (0.50) | TSHRLMNAKMT2AHSD17B10TDP1 | |
| SCHEMBL4738894 | 0.75 | TSHR (0.50) | TSHRTRPA1LMNAKMT2AHSD17B10 | |
| SCHEMBL14651687 | 0.74 | TRPA1 (0.67) | TRPA1SLC6A4HDAC3HDAC1HDAC2 | |
| SCHEMBL30266795 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170819-B1 | PROSTAGLANDIN PHARMACEUTICAL COMPOSITIONS | CTG PHARMA S R L (IT) | 2011-09-21 | — | — | EP | claimed |
| US-20100168216-A1 | PROSTAGLANDIN PHARMACEUTICAL COMPOSITIONS | CTG PHARMA S.R.L. (IT) | 2010-07-01 | — | — | US | claimed |
| EP-2170819-A1 | PROSTAGLANDIN PHARMACEUTICAL COMPOSITIONS | CTG Pharma S.r.l. (IT) | 2010-04-07 | — | — | EP | claimed |
| WO-2009156466-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CTG PHARMA S.R.L. (IT) | 2009-12-30 | — | — | WO | claimed |
| WO-2009109501-A2 | OCULAR PHARMACEUTICAL COMPOSITIONS | CTG PHARMA S.R.L. (IT) | 2009-09-11 | — | — | WO | claimed |
| WO-2009065926-A2 | NEW ANTICANCER COMPOUNDS | SULFIDRIS S.R.L. (IT) | 2009-05-28 | — | — | WO | claimed |
| WO-2009037556-A1 | NEW AGENTS FOR THE TREATMENT OF THE LOW URINARY TRACT DYSFUNCTIONS | CTG PHARMA S.R.L. (IT) | 2009-03-26 | — | — | WO | claimed |
| US-20090017003-A1 | THIOSULFONATE ANTI-INFLAMMATORY AGENTS | SULFIDRIS S.R.L. (IT) | 2009-01-15 | — | — | US | claimed |
| WO-2008146105-A1 | PROSTAGLANDIN PHARMACEUTICAL COMPOSITIONS | CTG PHARMA S.R.L. (IT) | 2008-12-04 | — | — | WO | claimed |
| WO-2008122356-A1 | CARDIOVASCULAR AGENTS | CTG PHARMA S.R.L. (IT) | 2008-10-16 | — | — | WO | claimed |
| EP-1980559-A1 | Cardiovascular agents | CTG Pharma S.r.l. (IT) | 2008-10-15 | — | — | EP | claimed |
| WO-2008077453-A1 | 5-FLUOROURACIL DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | SULFIDRIS, S.R.L. (IT) | 2008-07-03 | — | — | WO | claimed |
| EP-1939186-A1 | 5-Fluorouracil derivatives and their use for the treatment of cancer | Sulfidris S.r.l. (IT) | 2008-07-02 | — | — | EP | claimed |
| WO-2007101606-A1 | THIOSULFONATE ANTI-INFLAMMATORY AGENTS | SULFIDRIS S.R.L. (IT) | 2007-09-13 | — | — | WO | claimed |
| EP-1832575-A1 | Anti-inflammatory agents | Sulfidris S.r.l. (IT) | 2007-09-12 | — | — | EP | claimed |
| US-20260049991-A1 | SINGLE-MOLECULE PEPTIDE SEQUENCING USING GUANIDINYLATING AGENTS | GLYPHIC BIOTECHNOLOGIES INC (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4655289-A1 | SINGLE-MOLECULE PEPTIDE SEQUENCING USING GUANIDINYLATING AGENTS | Glyphic Biotechnologies, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| EP-0234600-A1 | Ligand/receptor pair-binding compounds | THE UPJOHN COMPANY (US) | 1987-09-02 | — | — | EP | disclosed |
| US-4614712-A | Immunoassays with luciferase labeled ligands or receptors | THE UPJOHN COMPANY (US) | 1986-09-30 | — | — | US | disclosed |
| EP-0117693-A2 | Enzyme-linked immunoassay, assay kits and pair-binding compounds | THE UPJOHN COMPANY (US) | 1984-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049991-A1 | SINGLE-MOLECULE PEPTIDE SEQUENCING USING GUANIDINYLATING AGENTS | CHAMP1, S100A11, TFIP11 | TSHR 3021/4885TRPA1 4171/4885LMNA 949/4885 |
| US-20100168216-A1 | PROSTAGLANDIN PHARMACEUTICAL COMPOSITIONS | PTGIS, PTGIR, PTGS1 | TSHR 3087/4885TRPA1 495/4885LMNA 2646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.